Omeros reports Q3 net loss from discontinued operations of $9.7 million
Omeros Corporation reported a net loss from discontinued operations, net of tax, of $9.7 million, or $0.15 per share, for the third quarter of 2025, compared to net income from discontinued operations, net of tax, of $4.9 million, or $0.08 per share, in the same period of 2024. The decrease was mainly due to a non-cash remeasurement of the OMIDRIA contract royalty asset, reflecting changes in royalty estimates from Rayner. Interest expense was a credit of $13.4 million in the third quarter of 2025, compared to $4.1 million in the prior year quarter, primarily due to a non-cash remeasurement adjustment on the OMIDRIA royalty obligation to DRI. Interest and other income totaled $0.6 million, down from $2.3 million in the third quarter of 2024, mainly due to lower cash and investments available. Business developments during the quarter included completion of above-market financing in July, progress on the Novo Nordisk transaction expected to close before year-end, and anticipation of the FDA's decision on narsoplimab in TA-TMA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034824), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.